强化降压治疗未显著降低糖尿病患者心血管事件发生率
Intensive blood pressure therapy did not cut cardiovascular events in adults with diabetes
研究显示,将成人2型糖尿病患者的收缩压降至120 mm Hg以下,未能显著减少心血管死亡、中风、心肌梗死或其他心血管事件的发生率,与将收缩压控制在140 mm Hg以下的标准治疗相比。尽管如此,更强化的降压治疗仍可能对2型糖尿病患者有轻微但有意义的健康益处。该研究分析了9,000多名50岁及以上、有高血压、2型糖尿病和心血管疾病史的巴西患者的数据,随访4年。
Intensive blood pressure-lowering treatment to reduce systolic pressure below 120 mm Hg in adults with type 2 diabetes, who are at increased risk of cardiovascular events, did not significantly reduce the incidence of cardiovascular death, stroke, heart attack or other cardiovascular events, compared to standard treatment targeting a systolic blood pressure of less than 140 mm Hg.
These were the results of new, independent, preliminary late-breaking science presented Saturday at the American Heart Association's Scientific Sessions 2026 in Chicago.
People with type 2 diabetes and high blood pressure are at increased risk of heart attacks and strokes. The American Heart Association/American College of Cardiology's 2025 Joint Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults notes that high blood pressure (≥130/80 mm Hg) is the No. 1 preventable risk factor for cardiovascular disease, including heart attack, stroke and heart failure, as well as kidney disease, cognitive decline and dementia. The guideline recommends keeping systolic blood pressure lower than 130 mm Hg and diastolic blood pressure less than 80 mm Hg and encourages reaching less than 120 mm Hg for people with increased risk of cardiovascular disease.
"These findings add important evidence about optimal blood pressure targets for adults with type 2 diabetes," said lead study author Karla Santo, M.D., Ph.D., head of Decentralized Clinical Studies and Innovative Trial Models at the Academic Research Organization of Einstein Hospital Israelita in São Paulo, Brazil.
"While this trial did not find a statistically significant reduction in major cardiovascular events, more intensive blood pressure treatment may still have modest yet meaningful health benefits for adults with type 2 diabetes," she said.
Researchers analyzed data from the OPTIMAL-DIABETES trial, which enrolled more than 9,000 men and women, ages 50 and older, at 33 sites in Brazil. Participants had elevated blood pressure (systolic blood pressure between 130 and 180 mm Hg), type 2 diabetes and a history of cardiovascular disease, subclinical cardiovascular disease (early heart or blood vessel disease that has not yet caused symptoms), chronic kidney disease or other cardiovascular risk factors.
Participants were randomly assigned to receive either intensive treatment to lower systolic blood pressure to below 120 mm Hg or standard treatment targeting a systolic level below 140 mm Hg. Researchers sought to determine if more intensive blood pressure management could reduce the incidence of cardiovascular death, stroke, heart attack or other cardiovascular events, including hospitalization due to heart failure or unstable angina (chest pain), compared to standard treatment.
Key findings
During a median follow-up of four years, participants who received intensive blood pressure-lowering treatment had about a 10% lower risk of experiencing a major cardiovascular event (cardiovascular death, stroke, heart attack, hospitalization due to heart failure or unstable angina). The results were not statistically significant.
In the intensive-treatment group, 286 participants (6.0%) experienced a major cardiovascular event, compared to 315 participants (6.7%) in the standard-treatment group.
The occurrence rate for kidney-related events was about 55% higher in the intensive-treatment group (270 participants, or 5.7%) compared to the standard-treatment group (175 participants, or 3.7%). These were primarily declines in kidney function with only a small number of participants developing end-stage renal disease. Importantly, the occurrence of end-stage renal disease was similar between groups. Serious adverse events were also similar between groups.
"These findings should not be interpreted as evidence that more intensive blood pressure lowering is ineffective for people with type 2 diabetes. Rather, they suggest that any cardiovascular benefit may be smaller than that observed in individuals without type 2 diabetes. As a result, even a large trial such as OPTIMAL-DIABETES may not have been able to definitively detect a modest treatment effect," said Otavio Berwanger, M.D., Ph.D., chair of the OPTIMAL-DIABETES trial steering committee and executive director at The George Institute for Global Health—Imperial College London in London, U.K.
Berwanger said the broader, important message is that blood pressure management for people with type 2 diabetes should remain individualized.
"A target below 120 mm Hg should not necessarily be applied universally to all patients, and treatment decisions should balance potential cardiovascular benefits, kidney effects, treatment burden and patient preferences," he said. "Ultimately, our study adds an important piece to the overall evidence base and highlights the need to consider the totality of evidence, rather than any single trial alone, when defining optimal blood pressure targets in patients with type 2 diabetes."
Study design, background, details and limitations
The OPTIMAL-DIABETES trial enrolled 9,476 adults, ages 50 and older (average age 65), with elevated systolic blood pressure between 130 and 180 mm Hg; type 2 diabetes; and established cardiovascular disease, subclinical cardiovascular disease, chronic kidney disease or cardiovascular risk factors, such as smoking, high cholesterol or age 75 or older. Among the participants, 62% identified as women; 42.5% self-identified as mixed-race adults; 41.9% as white adults; and 14.5% as Black adults.
Participants were enrolled in the study from August 2019 to October 2021 and followed up for four years at 33 sites in Brazil.
The analysis found that 2,697 participants (28.5%) had cardiovascular disease; 371 (3.9%) had subclinical cardiovascular disease; and 2,113 (22.6%) had chronic kidney disease at baseline.
At the beginning of the study, participants' average systolic blood pressure was 146 mm Hg, and diastolic blood pressure was 80 mm Hg. Participants were randomly assigned to either an intensive treatment group to lower systolic blood pressure below 120 mm Hg or a standard treatment group targeting systolic blood pressure less than 140 mm Hg. Blood pressure medications were adjusted throughout the study to reach those targets. The average systolic blood pressure throughout follow-up (excluding the first three months) was 122 mm Hg in the intensive-treatment group and 135 mm Hg in the standard-treatment group.
Researchers evaluated whether participants experienced cardiovascular death, heart attack, stroke, hospitalization for chest pain or heart failure during the four-year study period. They also examined deaths from any cause, each of these cardiovascular outcomes individually and kidney-related outcomes.
The main limitation of the study is that the trial was open-label, meaning participants and investigators knew which treatment strategy they were receiving. Additionally, the results may not be generalizable to populations outside Brazil.
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Intensive blood pressure therapy did not cut cardiovascular events in adults with diabetes (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-intensive-blood-pressure-therapy-cardiovascular.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com